NCI National Clinical Trials Network - Lead Academic Participant Sites

项目摘要 这笔赠款将为科罗拉多大学联盟癌症中心提供基础设施支持 及其临床护理合作伙伴UCHealth继续支持赠款的具体目标： 领导和参与具有科学重要性和临床相关性的非肿瘤坏死临床试验。 向科罗拉多州最大比例的癌症人口提供这些试验，并 怀俄明州。 快速激活、积累、精心提供患者协作，并准确报告研究 及时将相关数据提供给负责进行这些试验的NCTN部门。 在国家技术合作网络进程中培养和发展年轻的调查人员。 需要为管理、监管、临床协调和数据提供特定支持 管理层需要代表癌症安全有效地进行NCTN的临床试验 科罗拉多州和我们更广泛的集水区的患者。此外，我们将支持加强监测 并进行审计，以确保患者安全，并在我们所有的临床护理地点适当地进行试验。 质量评估和改进是我们NCTN计划的一个主要特点。 我们认真对待参与制定新概念的任务， 我们的实验室科学家在这些翻译项目中，以及培养新的初级调查人员 进一步说明NCTN中治疗试验的临床影响。对话和沟通是关键。在 我们的机构，我们为整个系统(LAPS)的调查人员创建了一个极好的论坛 执行委员会)，代表所有模式和以疾病为导向的团体，优先考虑和 致力于新的试验，监测应计利润和与这些试验的进行有关的任何其他问题 在我们的系统中。我们支持调查人员、工作人员和科学家参加NCTN的旅行 会议和委员会。 这笔赠款将支持一项新的倡议。许多新的试验是多肿瘤的，和/或 需要患者肿瘤的分子特征，以匹配患者进行适当的治疗 协议。我们的机构已经有一个“T3”CRA团队来处理多个肿瘤学的“篮子”试验，我们 拥有一个功能齐全的分子肿瘤委员会。在单独的努力中，我们正在开发针对患者的 分子数据库将获得内部和外部分子肿瘤数据，并将 可搜索的。一个定期审查这些数据库的导航员职位，分子驱动的临床 试验，并指导患者和临床医生将患者与合适的试验相匹配，可能会改善我们的 从这些审判中获利。

Project Summary This grant will provide infrastructure support to the University of Colorado Consortium Cancer Center and its clinical care partner UCHealth to continue to support the specific aims of the grant:  To lead and participate in scientifically important and clinically relevant NCTN clinical trials.  To make these trials available to the greatest proportion of the cancer population of Colorado and Wyoming.  To rapidly activate, accrue, caringly provide patient coordination, and accurately report research related data in a timely way to the NCTN components responsible for conducting these trials.  To foster and develop young investigators in the NCTN process. Specific support is requested for the administrative, regulatory, clinical coordination, and data management needs to conduct clinical trials of the NCTN safely and efficiently on behalf of the cancer patients in Colorado and our wider catchment area. In addition, we will support enhanced monitoring and auditing to ensure patient safety and proper conduct of the trials at all our sites of clinical care. Quality assessment and improvement are a central features of our NCTN program. We take seriously the mandate to participate in the development of new concepts, the contribution of our laboratory scientists in these translational projects, and the fostering of new junior investigators to further the clinical impact of therapeutic trials in the NCTN. Dialog and communication are key. Within our institution, we have created a superb forum for our investigators across the entire system (the LAPS Executive Committee) that represents all modalities and disease-oriented groups to prioritize and commit to new trials, to monitor accrual and any other issues related to the conduct of these trials across our system. We support travel for investigators, staff, and scientists to participate in the NCTN meetings and committees. A new initiative will be supported with this grant. Many of the new trials are multi-oncologic, and/or require molecular characterization of the patient's tumor to match the patient to appropriate treatment protocols. Our institution already has a “T3” CRA team to handle multi-oncologic “basket” trials, and we have a fully functional Molecular Tumor Board. In separate efforts, we are developing patient-specific molecular databases that will obtain both internal and external molecular tumor data, and will be searchable. A navigator position to regularly review these databases, the molecularly-driven clinical trials, and guide patients and clinicians to match the patients to the suitable trials may improve our accrual to these trials.